Cat. No. | Product name | CAS No. |
DCC1918 |
Eh-201
Arginase Inhibitor, activating EPO-mediated mitochondrial function and haemoglobin expression, stimulating melanogenesis by MAP kinase activation and tyrosinase upregulation |
55327-45-2 |
DCC1919 |
Ehi1471
Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
DCC1920 |
Ehi2119
Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
DCC1921 |
Ehi2225
Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
DCC1922 |
Eht5372
Novel Mirk kinase inhibitor, inhibiting DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites, blocking the in vivo growth of pancreatic cancer cells |
1425945-60-3 |
DCC1923 |
Eidd-1619
Novel water-soluble analog of progesterone |
1659302-92-7 |
DCC1924 |
Eidd-1723
Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity |
1659302-89-2 |
DCC1925 |
Eif4a Inhibitor 28
Novel RNA-competitive, ATP-uncompetitive eIF4A Inhibitor, decreasing BJAB Burkitt lymphoma cell viability, engaging a novel pocket in the RNA groove of eIF4A and inhibiting unwinding activity by interfering with proper RNA binding and suppressing ATP hydr |
|
DCC1926 |
Ejmch-6
Novel anti-bacterial agent, targeting the MmpL3 transporter in Mycobacterium abscessus |
|
DCC1927 |
Ejr-866-75
Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase |
|
DCC1928 |
Ejr-866-81
Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase |
|
DCC1929 |
El-0052
Novel etomidate analogue, enhancing GABA A receptors currents with a concentration for 50% of maximal effect (EC 50 ) of 0.98 {plus minus} 0.02 μM, which was about three times more potent than etomidate (3.07 {plus minus} 1.67 μM), retaining the favorable |
|
DCC1930 |
El-228
Novel inhibitor of Aurora B kinase |
|
DCC1931 |
Ela23-32
Novel ligand of the apelin receptor (APJ), possessing high affinity for APJ (Ki 4.6 nM) and producing cardiorenal effects in vivo similar to those of ELA |
|
DCC1932 |
elaidyl-sulfamide
Oleoylethanolamide-modelled PPAR |
945009-57-4 |
DCC1933 |
Elnd006
Novel γ-secretase inhibitor |
959997-22-9 |
DCC1934 |
Elovl1 Inhibitor 22
Novel highly potent, selective, and CNS-penetrant inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme |
|
DCC1935 |
Elx-02
Eukaryotic Ribosomal Selective Glycoside (ERSG), inducing read-through of premature stop codons (PSCs) and resulting in translation of full-length protein |
1375073-95-2 |
DCC1936 |
Em20-25
Novel BCL-2 inhibitor, neutralizing the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitizing BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine |
141266-44-6 |
DCC1937 |
em-800
High affinity ligand for estrogen receptor- |
182167-03-9 |
DCC1938 |
Emac4001
Novel potent antitumor agent, inducing apoptosis in a panel of tumor cell lines |
|
DCC1939 |
Emd-1204831
Novel potent and highly selective c-Met inhibitor |
1362819-72-4 |